Islatravir (MK-8591)
98%
- Product Code: 63495
CAS:
865363-93-5
| Molecular Weight: | 293.25 g./mol | Molecular Formula: | C₁₂H₁₂FN₅O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Islatravir is primarily investigated for its application in the treatment and prevention of HIV infections. It functions as a nucleoside reverse transcriptase translocation inhibitor (NRTTI), effectively blocking the reverse transcriptase enzyme that HIV uses to replicate its genetic material. This mechanism makes it a potent candidate for both therapeutic and prophylactic use. In clinical trials, Islatravir has shown promise as a long-acting oral medication, potentially reducing the frequency of dosing compared to existing antiretroviral therapies. Additionally, it is being explored in combination with other antiretroviral drugs to enhance efficacy and reduce the risk of resistance. Beyond treatment, Islatravir is also being studied for its potential in pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk populations. Its long-acting properties could offer a more convenient and discreet option for individuals seeking protection against HIV.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $2,371.38 |
+
-
|
Islatravir (MK-8591)
Islatravir is primarily investigated for its application in the treatment and prevention of HIV infections. It functions as a nucleoside reverse transcriptase translocation inhibitor (NRTTI), effectively blocking the reverse transcriptase enzyme that HIV uses to replicate its genetic material. This mechanism makes it a potent candidate for both therapeutic and prophylactic use. In clinical trials, Islatravir has shown promise as a long-acting oral medication, potentially reducing the frequency of dosing compared to existing antiretroviral therapies. Additionally, it is being explored in combination with other antiretroviral drugs to enhance efficacy and reduce the risk of resistance. Beyond treatment, Islatravir is also being studied for its potential in pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk populations. Its long-acting properties could offer a more convenient and discreet option for individuals seeking protection against HIV.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :